Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 13 04:00PM ET
0.8574
Dollar change
+0.0050
Percentage change
0.59
%
IndexRUT P/E- EPS (ttm)-0.18 Insider Own1.44% Shs Outstand290.26M Perf Week-1.45%
Market Cap251.25M Forward P/E- EPS next Y-0.26 Insider Trans0.84% Shs Float287.13M Perf Month-10.51%
Income-46.16M PEG- EPS next Q-0.06 Inst Own27.54% Short Float19.85% Perf Quarter-26.72%
Sales4.70M P/S53.46 EPS this Y22.12% Inst Trans18.37% Short Ratio15.31 Perf Half Y-39.62%
Book/sh0.14 P/B6.13 EPS next Y-25.93% ROA-74.87% Short Interest57.00M Perf Year133.05%
Cash/sh0.13 P/C6.49 EPS next 5Y- ROE-103.30% 52W Range0.36 - 2.11 Perf YTD49.11%
Dividend Est.- P/FCF- EPS past 5Y41.20% ROI-101.17% 52W High-59.27% Beta3.83
Dividend TTM- Quick Ratio2.58 Sales past 5Y8.52% Gross Margin67.04% 52W Low138.17% ATR (14)0.06
Dividend Ex-Date- Current Ratio2.58 EPS Y/Y TTM45.81% Oper. Margin-1115.79% RSI (14)40.99 Volatility6.95% 6.82%
Employees65 Debt/Eq0.17 Sales Y/Y TTM- Profit Margin-982.04% Recom1.00 Target Price6.25
Option/ShortYes / Yes LT Debt/Eq0.12 EPS Q/Q15.58% Payout- Rel Volume1.40 Prev Close0.85
Sales Surprise184.00% EPS Surprise9.09% Sales Q/Q- EarningsNov 08 BMO Avg Volume3.72M Price0.86
SMA20-5.03% SMA50-8.83% SMA200-33.99% Trades Volume5,226,587 Change0.59%
Date Action Analyst Rating Change Price Target Change
Oct-15-24Initiated Maxim Group Buy $4
Mar-01-23Upgrade Chardan Capital Markets Neutral → Buy $3.50
Aug-23-22Initiated Mizuho Buy $5
Jun-15-22Resumed ROTH Capital Buy $8
Jun-02-22Initiated Cantor Fitzgerald Overweight $4.50
Jul-26-21Initiated Noble Capital Markets Outperform
Jun-11-21Downgrade ROTH Capital Buy → Neutral $10 → $6
May-07-21Downgrade Cantor Fitzgerald Overweight → Neutral
Feb-09-21Downgrade Chardan Capital Markets Buy → Neutral $0.70 → $13
Feb-04-21Upgrade H.C. Wainwright Neutral → Buy $4.50
Dec-11-24 07:02AM
Nov-27-24 07:09AM
Nov-20-24 07:30AM
Nov-19-24 07:02AM
Nov-14-24 04:40PM
03:32PM Loading…
03:32PM
Nov-09-24 02:14AM
02:05AM
Nov-08-24 11:15AM
06:45AM
Nov-07-24 06:30AM
Oct-28-24 06:30AM
Oct-22-24 07:02AM
Oct-17-24 07:30AM
Oct-16-24 03:03PM
07:00AM Loading…
Oct-10-24 07:00AM
Oct-09-24 05:35PM
06:30AM
Oct-02-24 06:30AM
Sep-24-24 07:30AM
Sep-09-24 06:30AM
Sep-05-24 07:00AM
Sep-03-24 07:30AM
Aug-28-24 06:30AM
Aug-26-24 07:02AM
Aug-08-24 10:49PM
05:30PM
06:45AM
06:27AM
Aug-05-24 06:30AM
03:22PM Loading…
Aug-02-24 03:22PM
Jul-31-24 09:15PM
04:15PM
Jul-29-24 07:02AM
Jul-25-24 06:30AM
Jul-11-24 08:45AM
Jul-06-24 06:39AM
Jun-24-24 09:40AM
06:40AM
Jun-21-24 07:00AM
Jun-20-24 08:23AM
06:30AM
Jun-14-24 07:15AM
Jun-05-24 09:25AM
May-31-24 08:36AM
May-29-24 07:15AM
May-28-24 07:02AM
May-24-24 08:10AM
May-20-24 07:00AM
May-15-24 07:30AM
06:30AM
03:02AM
01:12AM
May-14-24 11:53AM
08:00AM
06:43AM
May-10-24 04:05PM
07:45AM
May-08-24 06:00AM
May-03-24 07:30AM
May-02-24 07:15AM
Apr-29-24 08:30AM
06:45AM
Apr-28-24 11:59AM
Apr-26-24 12:35PM
09:05AM
06:30AM
Apr-19-24 07:13AM
Apr-16-24 10:53PM
Apr-12-24 07:30AM
Apr-10-24 07:02AM
Apr-08-24 12:13PM
10:57AM
06:30AM
Apr-05-24 03:30PM
07:02AM
Apr-02-24 10:50PM
07:00PM
03:15PM
08:00AM
Apr-01-24 06:08PM
05:43PM
Mar-25-24 11:58AM
07:32AM
Mar-18-24 06:30AM
Mar-13-24 08:00AM
Mar-07-24 05:28AM
Mar-06-24 07:30AM
Feb-28-24 08:00AM
Feb-26-24 04:34PM
08:30AM
Feb-22-24 04:05PM
12:56PM
Feb-21-24 04:05PM
Feb-20-24 10:26AM
Feb-14-24 07:30AM
Jan-31-24 08:00AM
Jan-16-24 07:30AM
Dec-21-23 06:30AM
Dec-19-23 07:30AM
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fernandes PrabhavathiDirectorNov 26 '24Buy0.9110,0009,09510,000Dec 02 04:15 PM
Castillo KirstenDirectorNov 22 '24Buy0.9125,00022,84875,000Nov 26 04:50 PM
RAMESH KUMARDirectorAug 16 '24Proposed Sale1.25116,705145,905Aug 16 04:16 PM